Drug–drug interactions (DDIs) and associated toxicity from cardiovascular drugs represents
a major problem for effective co-administration of cardiovascular therapeutics. A significant …

P-glycoprotein (Pgp) is an ATP-binding cassette (ABC) transporter that plays a major role in
cardiovascular drug disposition by effluxing a chemically and structurally diverse range of …

Digoxin is the recommended substrate for assessment of P-glycoprotein (P-gp)-mediated
drug–drug interactions (DDIs) in vivo. The overall aim of our study was to investigate the …

Digoxin, which has a very narrow therapeutic window, is one of the most commonly
prescribed drugs in the treatment of congestive heart failure. In some cases of atrial …

The clinical pharmacokinetics and in vitro inhibition of digoxin were examined to predict the
P‐glycoprotein (P‐gp) component of drug–drug interactions. Coadministered drugs (co …

Digoxin, an orally administered cardiac glycoside cardiovascular drug, has a narrow
therapeutic window. Circulating digoxin levels (maximal concentration of∼ 1.5 ng/ml) …

The P-glycoprotein (Pgp) transporter plays a central role in drug disposition by effluxing a
chemically diverse range of drugs from cells through conformational changes and ATP …

To support drug development and registration, Caco-2 cell monolayer assays have
previously been set up and validated to determine whether candidate drugs are substrates …

Regulatory interest is increasing for drug transporters generally and P-glycoprotein (Pgp) in
particular, primarily in the area of drug–drug interactions. To aid in both identifying and …

Background—Although quinidine is known to elevate plasma digoxin concentrations, the
mechanism underlying this interaction is not fully understood. Digoxin is not extensively …